Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGA ...
Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early ...
Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events ---- ...
Broadcast Retirement Network's Jeffrey Snyder discusses the latest approaches to Alzheimer's research with clinical ...
Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-4 ...
Fortinet, Inc. ( FTNT) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDT Anthony Luscri - Vice President of Investor Relations Ken Xie - Co-Founder, Chairman & CEO Christiane Ohlgart - Chief Accounting ...
When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued ...
Fieldwork in the wet grasslands of the Brazilian Cerrado often means long trudges through head-high reeds, following tapir ...
Explore the potential and pitfalls of gamification in education, questioning its true impact on cognitive development and learning outcomes.
Q1 2026 Earnings Call May 6, 2026 8:00 AM EDTCompany ParticipantsYehoshua Nir - CEO & DirectorAsaf Alperovitz - ...
YouTube on MSN
How statins quietly disrupt muscle cells
The biology behind muscle pain: calcium chaos, microscopic damage, and the overlooked mechanism that explains how statins can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results